Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties

Journal of Medicinal Chemistry

Volumn 59, Issue 6, 2016, Pages 2497-2511

  Johansson, Anders ^a   Löfberg, Christian ^a   Antonsson, Madeleine ^a   Von Unge, Sverker ^a   Hayes, Martin A ^a   Judkins, Robert ^a   Ploj, Karolina ^a   Benthem, Lambertus ^a   Lindén, Daniel ^a   Brodin, Peter ^a   Wennerberg, Marie ^a   Fredenwall, Marléne ^a   Li, Lanna ^a   Persson, Joachim ^a   Bergman, Rolf ^a   Pettersen, Anna ^a   Gennemark, Peter ^a   Hogner, Anders ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 HYDROXYAZETIDIN 1 YL)[5 (4 METHOXY PHENYL) 1,3,4 OXADIAZOL 2 YL]METHANONE; 1 [5 (4 METHOXYPHENYL) 1,3,4 OXADIAZOLE 2 CARBONYL]AZETIDIN 3 YL METHANE SULFONATE; 4 (2 OXA 6 AZASPIRO[3.3]HEPT 6 YLMETHYL)PHENOL; 4 [1 [5 (4 METHOXYPHENYL) 1,3,4 OXADIAZOLE 2 CARBONYL]AZETIDIN 3 YLOXY]BENZALDEHYDE; 6 [4 (AZETIDIN 3 YLOXY)BENZYL] 2 OXA 6 AZASPIRO[3.3]HEPTANE; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; TERT BUTYL 3 [4 (2 OXA 6 AZASPIRO[3.3]HEPT 6 YLMETHYL)PHENOXY]AZETIDINE 1 CARBOXYLATE; UNCLASSIFIED DRUG; [3 [4 (2OXA 6 AZASPIRO[3.3]HEPTAN 6 YLMETHYL)PHENOXY]AZETIDIN 1 YL][5 (4 METHOXY METHOXYPHENYL) 1,3,4 OXADIAZOL 2 YL]METHANONE; ANTIOBESITY AGENT; AZD1979; AZETIDINE DERIVATIVE; LIPID; MCH1R PROTEIN, MOUSE; OXADIAZOLE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; EX VIVO STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; LIPOPHILICITY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; RECEPTOR OCCUPANCY; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; BRAIN; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTI-OBESITY AGENTS; AZETIDINES; BODY WEIGHT; BRAIN; DRUG DISCOVERY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; LIPIDS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; OXADIAZOLES; POTASSIUM CHANNEL BLOCKERS; RECEPTORS, SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84962185125     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01654     Document Type: Article

References (59)

1. Colman, E. Food and drug administration's obesity drug guidance document: a short history Circulation 2012, 125, 2156-2164 10.1161/CIRCULATIONAHA.111.028381
2. Guh, D. P.; Zhang, W.; Bansback, N.; Amarsi, Z.; Birmingham, C. L.; Anis, A. H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis BMC Public Health 2009, 9, 88 10.1186/1471-2458-9-88
3. Malik, V. S.; Willett, W. C.; Hu, F. B. Global obesity: trends, risk factors and policy implications Nat. Rev. Endocrinol. 2013, 9, 13-27 10.1038/nrendo.2012.199
4. Gouni-Berthold, I.; Bruning, J. C.; Berthold, H. K. Novel approaches to the pharmacotherapy of obesity Curr. Pharm. Des. 2013, 19, 4938-4952 10.2174/13816128113199990302
5. Sargent, B. J.; Moore, N. A. New central targets for the treatment of obesity Br. J. Clin. Pharmacol. 2009, 68, 852-860 10.1111/j.1365-2125.2009.03550.x
6. Takase, K.; Kikuchi, K.; Tsuneoka, Y.; Oda, S.; Kuroda, M.; Funato, H. Meta-analysis of melanin-concentrating hormone signaling-deficient mice on behavioral and metabolic phenotypes PLoS One 2014, 9, e99961 10.1371/journal.pone.0099961
7. Kilduff, T. S.; de Lecea, L. Mapping of the mRNAs for the hypocretin/orexin and melanin-concentrating hormone receptors: networks of overlapping peptide systems J. Comp. Neurol. 2001, 435, 1-5 10.1002/cne.1189
8. Hervieu, G. J.; Cluderay, J. E.; Harrison, D.; Meakin, J.; Maycox, P.; Nasir, S.; Leslie, R. A. The distribution of the mRNA and protein products of themelanin-concentrating hormone (MCH) receptor gene, SLC-1, in the central nervous system of the rat Eur. J. Neurosci. 2000, 12, 1194-1216 10.1046/j.1460-9568.2000.00008.x
9. Shimada, M.; Tritos, N. A.; Lowell, B. B.; Flier, J. S.; Maratos-Flier, E. Mice lacking melanin-concentrating hormone are hypophagic and lean Nature (London, U. K.) 1998, 396, 670-674 10.1038/25341
10. Astrand, A.; Bohloody, M.; Larsdotter, S.; Mahlapuu, M.; Andersén, H.; Tornell, J.; Ohlsson, C.; Snaith, M.; Morgan, D. G. A. Mice lacking melanin-concentrating hormone receptor 1 demonstrate increased heart rate associated with altered autonomic activity Am. J. Physiol.: Regul. Integr. Comp. Physiol. 2004, 287, R749-R758 10.1152/ajpregu.00134.2004
11. Marsh, D. J.; Weingarth, D. T.; Novi, D. E.; Chen, H. Y.; Trumbauer, M. E.; Chen, A. S.; Guan, X. M.; Jiang, M. M.; Feng, Y.; Camacho, R. E.; Shen, Z.; Frazier, E. G.; Yu, H.; Metzger, J. M.; Kuca, S. J.; Shearman, L. P.; Gopal-Truter, S.; MacNeil, D. J.; Strack, A. M.; MacIntyre, D. E.; Van der Ploeg, L. H.; Qian, S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 3240-3245 10.1073/pnas.052706899
12. Ito, M.; Ishihara, A.; Gomori, A.; Matsushita, H.; Ito, M.; Metzger, J. M.; Marsh, D. J.; Haga, Y.; Iwaasa, H.; Tokita, S.; Takenaga, N.; Sato, N.; MacNeil, D. J.; Moriya, M.; Kanatani, A. Mechanism of the anti-obesity effects induced by a novel melanin-concentrating hormone 1-receptor antagonist in mice Br. J. Pharmacol. 2010, 159, 374-383 10.1111/j.1476-5381.2009.00536.x
13. Goldstein, C.; Schroeder, J. C.; Fortin, J.-P.; Goss, J. M.; Schaus, S. E.; Beinborn, M.; Kopin, A. S. Two naturally occurring mutations in the type 1 melanin-concentrating hormone receptor abolish agonist-induced signaling J. Pharmacol. Exp. Ther. 2010, 335, 799-806 10.1124/jpet.110.174029
14. Macneil, D. J. The role of melanin-concentrating hormone and its receptors in energy homeostasis Front. Endocrinol. (Lausanne, Switz.) 2013, 4, 49 10.3389/fendo.2013.00049
15. Tan, C. P.; Sano, H.; Iwaasa, H.; Pan, J.; Sailer, A. W.; Hreniuk, D. L.; Feighner, S. D.; Palyha, O. C.; Pong, S.-S.; Figueroa, D. J.; Austin, C. P.; Jiang, M. M.; Yu, H.; Ito, J.; Ito, M.; Ito, M.; Guan, X. M.; MacNeil, D. J.; Kanatani, A.; Van der Ploeg, L. H. T.; Howard, A. D. Melanin-concentrating hormone receptor subtypes 1 and 2: species-specific gene expression Genomics 2002, 79, 785-792 10.1006/geno.2002.6771
16. Chee, M. J.; Pissios, P.; Prasad, D.; Maratos-Flier, E. Expression of melanin-concentrating hormone receptor 2 protects against diet-induced obesity in male mice Endocrinology 2014, 155, 81-88 10.1210/en.2013-1738
17. Mihalic, J. T.; Chen, X.; Fan, P.; Chen, X.; Fu, Y.; Liang, L.; Reed, M.; Tang, L.; Chen, J.-L.; Jaen, J.; Li, L.; Dai, K. Discovery of a novel series of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity Bioorg. Med. Chem. Lett. 2011, 21, 7001-7005 10.1016/j.bmcl.2011.09.110
18. Motani, A. S.; Luo, J.; Liang, L.; Mihalic, J. T.; Chen, X.; Tang, L.; Li, L.; Jaen, J.; Chen, J. L.; Dai, K. Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models Pharmacol. Res. Perspect. 2013, 1, e00003 10.1002/prp2.3
19. Chen, X.; Mihalic, J.; Fan, P.; Liang, L.; Lindstrom, M.; Wong, S.; Ye, Q.; Fu, Y.; Jaen, J.; Chen, J.-L.; Dai, K.; Li, L. Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2 Bioorg. Med. Chem. Lett. 2012, 22, 363-366 10.1016/j.bmcl.2011.10.125
20. Shimazaki, T.; Yoshimizu, T.; Chaki, S. Melanin-concentrating hormone MCH1 receptor antagonists a potential new approach to the treatment of depression and anxiety disorders CNS Drugs 2006, 20, 801 10.2165/00023210-200620100-00002
21. Ito, M.; Gomori, A.; Suzuki, J.; Tsujioka, S.; Sasaki, M.; Matsuda, M.; Bednarek, M. A.; Ito, M.; Ishihara, A.; Iwaasa, H.; Macneil, D. J.; Kanatani, A. Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice J. Endocrinol. 2008, 198, 309-315 10.1677/JOE-08-0087
22. Parks, G. S.; Okumura, S. M.; Gohil, K.; Civelli, O. Mice lacking Melanin Concentrating Hormone 1 receptor are resistant to seizures Neurosci. Lett. 2010, 484, 104-107 10.1016/j.neulet.2010.08.018
23. Johansson, A. Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists Expert Opin. Ther. Pat. 2011, 21, 905-925 10.1517/13543776.2011.575063
24. Luthin, D. R. Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists Life Sci. 2007, 81, 423-440 10.1016/j.lfs.2007.05.029
25. Johansson, A.; Lofberg, C. Novel MCH1 receptor antagonists: a patent review Expert Opin. Ther. Pat. 2015, 25, 193-207 10.1517/13543776.2014.993382
26. Szalai, K. K.; Beke, G.; Eles, J.; Kitka, T.; Kovacs, P.; Nagy, J.; Farkas, S.; Boros, A. Recent patents on novel MCH1 receptor antagonists as potential anti-obesity drugs Recent Pat. CNS Drug Discovery 2014, 9, 122-140 10.2174/1574889809666140613115426
27. Hogberg, T.; Frimurer, T. M.; Sasmal, P. K. Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment? Bioorg. Med. Chem. Lett. 2012, 22, 6039-6047 10.1016/j.bmcl.2012.08.025
28. Bingham, M.; Rankovic, Z. Medicinal chemistry challenges in CNS drug discovery RSC Drug Discovery Ser. 2012, 28, 465-509 10.1039/9781849734943-00465
29. Moore, N. A.; Sargent, B. J.; Guzzo, P. R.; Surman, M. D. From preclinical to clinical development: the example of a novel treatment for obesity Neurobiol. Dis. 2014, 61, 47-54 10.1016/j.nbd.2013.07.009
30. Berglund, S.; Egner, B. J.; Graden, H.; Graden, J.; Morgan, D. G.; Inghardt, T.; Giordanetto, F. Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition Bioorg. Med. Chem. Lett. 2009, 19, 4268-4273 10.1016/j.bmcl.2009.05.067
31. Berglund, S.; Egner, B. J.; Graden, H.; Graden, J.; Morgan, D. G.; Inghardt, T.; Giordanetto, F. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities Bioorg. Med. Chem. Lett. 2009, 19, 4274-4279 10.1016/j.bmcl.2009.05.066
32. Berglund, S.; Egner, B. J.; Graden, H.; Graden, J.; Morgan, D. G.; Inghardt, T.; Giordanetto, F. Discovery of 1,3-disubstituted-1H-pyrrole derivatives as potent melanin-concentrating hormone receptor 1 (MCH-R1) antagonists Bioorg. Med. Chem. Lett. 2008, 18, 4859-4863 10.1016/j.bmcl.2008.07.079
33. Giordanetto, F.; Karlsson, O.; Lindberg, J.; Larsson, L. O.; Linusson, A.; Evertsson, E.; Morgan, D. G.; Inghardt, T. Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists Bioorg. Med. Chem. Lett. 2007, 17, 4232-4241 10.1016/j.bmcl.2007.05.034
34. Thomsen, W.; Frazer, J.; Unett, D. Functional assays for screening GPCR targets Curr. Opin. Biotechnol. 2005, 16, 655-665 10.1016/j.copbio.2005.10.008
35. 35S]GTPγS binding assay: approaches and applications in pharmacology Life Sci. 2003, 74, 489-508 10.1016/j.lfs.2003.07.005
36. GOSTAR: GVK Bio Online Structure Activity Relationship Database; GVK Bio; https://gostardb.com/gostar/ (Accessed September 12 2013).
37. a and PSA, methods from ACD/labs were used throughout the chemistry program. Advanced Chemistry Development, Inc.: Toronto, ON, Canada, www.acdlabs.com. Calculations of clogP were made using clogP version 4.3. Pomona College and Biobyte Inc.: Claremont, CA, USA. These can be easily accessed through the internal C-lab portal: http://dalkescientific.com/writings/CLab-EuroQSAR2008.pdf.
38. Philippe, C.; Haeusler, D.; Fuchshuber, F.; Spreitzer, H.; Viernstein, H.; Hacker, M.; Wadsak, W.; Mitterhauser, M. Comparative autoradiographic in vitro investigation of melanin concentrating hormone receptor 1 ligands in the central nervous system Eur. J. Pharmacol. 2014, 735, 177-183 10.1016/j.ejphar.2014.04.020
39. Smith, D. G.; Hegde, L. G.; Wolinsky, T. D.; Miller, S.; Papp, M.; Ping, X.; Edwards, T.; Gerald, C. P.; Craig, D. A. The effects of stressful stimuli and hypothalamic-pituitary-adrenal axis activation are reversed by the melanin-concentrating hormone 1 receptor antagonist SNAP 94847 in rodents Behav. Brain Res. 2009, 197, 284-291 10.1016/j.bbr.2008.08.026
40. Ito, M.; Sakamoto, T.; Suzuki, T.; Egashira, S.; Moriya, M.; Ishihara, A.; Iwaasa, H.; Matsushita, H.; Nakase, K.; Wallace, M. A.; Dean, D.; Sato, N.; Tokita, S.; Kanatani, A. Identification and characterization of a selective radioligand for melanin-concentrating hormone 1-receptor (MCH1R) Bioorg. Med. Chem. Lett. 2009, 19, 2835-2839 10.1016/j.bmcl.2009.03.102
41. Ito, M.; Ishihara, A.; Gomori, A.; Egashira, S.; Matsushita, H.; Mashiko, S.; Ito, J.; Ito, M.; Nakase, K.; Haga, Y.; Iwaasa, H.; Suzuki, T.; Ohtake, N.; Moriya, M.; Sato, N.; MacNeil, D. J.; Takenaga, N.; Tokita, S.; Kanatani, A. Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice Eur. J. Pharmacol. 2009, 624, 77-83 10.1016/j.ejphar.2009.10.004
42. Lagu, B.; Wetzel, J.; Marzabadi, M. R.; Deleon, J. E.; Gluchowski, C.; Noble, S.; Nagarathnam, D.; Chiu, G. Preparation and use of arylpyrimidines as selective melanin concentrating hormone-1 (mch-1) receptor antagonists. WO2002006245, January 24, 2002.
43. Goss, J. M.; Schaus, S. E. Enantioselective synthesis of SNAP-7941: chiral dihydropyrimidone Inhibitor of MCH1-r J. Org. Chem. 2008, 73, 7651-7656 10.1021/jo801463j
44. Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers J. Med. Chem. 2002, 45, 3844-3853 10.1021/jm0208875
45. Washburn, W. N.; Manfredi, M.; Devasthale, P.; Zhao, G.; Ahmad, S.; Hernandez, A.; Robl, J. A.; Wang, W.; Mignone, J.; Wang, Z.; Ngu, K.; Pelleymounter, M. A.; Longhi, D.; Zhao, R.; Wang, B.; Huang, N.; Flynn, N.; Azzara, A. V.; Barrish, J. C.; Rohrbach, K.; Devenny, J. J.; Rooney, S.; Thomas, M.; Glick, S.; Godonis, H. E.; Harvey, S. J.; Cullen, M. J.; Zhang, H.; Caporuscio, C.; Stetsko, P.; Grubb, M.; Maxwell, B. D.; Yang, H.; Apedo, A.; Gemzik, B.; Janovitz, E. B.; Huang, C.; Zhang, L.; Freeden, C.; Murphy, B. J. Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate J. Med. Chem. 2014, 57, 7509-7522 10.1021/jm500026w
46. Hoegberg, T.; Stroem, P.; Ebner, M.; Raemsby, S. Cyanide as an efficient and mild catalyst in the aminolysis of esters J. Org. Chem. 1987, 52, 2033-2036 10.1021/jo00386a025
47. Ulven, T.; Frimurer, T. M.; Receveur, J.-M.; Little, P. B.; Rist, O.; Norregaard, P. K.; Hoegberg, T. 6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode J. Med. Chem. 2005, 48, 5684-5697 10.1021/jm050103y
48. Rivera, G.; Bocanegra-Garcia, V.; Galiano, S.; Cirauqui, N.; Ceras, J.; Perez, S.; Aldana, I.; Monge, A. Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity Curr. Med. Chem. 2008, 15, 1025-1043 10.2174/092986708784049621
49. Bostrom, J.; Greenwood, J. R.; Gottfries, J. Assessing the performance of OMEGA with respect to retrieving bioactive conformations J. Mol. Graphics Modell. 2003, 21, 449-462 10.1016/S1093-3263(02)00204-8
50. Bostrom, J.; Hogner, A.; Llinas, A.; Wellner, E.; Plowright, A. T. Oxadiazoles in medicinal chemistry J. Med. Chem. 2012, 55, 1817-1830 10.1021/jm2013248
51. Wan, H.; Holmen, A.; Nagard, M.; Lindberg, W. Rapid screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis combined with short-end injection J. Chromatogr. A 2002, 979, 369-377 10.1016/S0021-9673(02)01262-1
52. Davis, A. M.; Wood, D. J. Quantitative structure-activity relationship models that stand the test of time Mol. Pharmaceutics 2013, 10, 1183-1190 10.1021/mp300466n
53. Carreira, E. M.; Fessard, T. C. Four-membered ring-containing spirocycles: synthetic strategies and opportunities Chem. Rev. 2014, 114, 8257-8322 10.1021/cr500127b
54. Wuitschik, G.; Rogers-Evans, M.; Buckl, A.; Bernasconi, M.; Marki, M.; Godel, T.; Fischer, H.; Wagner, B.; Parrilla, I.; Schuler, F.; Schneider, J.; Alker, A.; Schweizer, W. B.; Muller, K.; Carreira, E. M. Spirocyclic oxetanes: synthesis and properties Angew. Chem., Int. Ed. 2008, 47, 4512-4515 10.1002/anie.200800450
55. Johansson, L. A. M.; Judkins, R. A.; Li, L.; Lofberg, B. C. I.; Persson, J. Preparation of (azetidinyl)oxadiazolylmethanone derivatives for use as MCH1 receptor modulators. WO2010125390, April 29, 2010.
56. ClinicalTrials.gov Identifier: NCT02072993.
57. Dost, J.; Heschel, M.; Stein, J. Preparation of 1,3,4-oxadiazole-2-carboxylic acid derivatives J. Prakt. Chem. 1985, 327, 109-116 10.1002/prac.19853270116
58. Borowsky, B.; Durkin, M. M.; Ogozalek, K.; Marzabadi, M. R.; DeLeon, J.; Heurich, R.; Lichtblau, H.; Shaposhnik, Z.; Daniewska, I.; Blackburn, T. P.; Branchek, T. A.; Gerald, C.; Vaysse, P. J.; Forray, C. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist Nat. Med. (N. Y., NY, U. S.) 2002, 8, 825-830 10.1038/nm741
59. Lemurell, M.; Ulander, J.; Winiwarter, S.; Dahlen, A.; Davidsson, O.; Emtenaes, H.; Broddefalk, J.; Swanson, M.; Hovdal, D.; Plowright, A. T.; Pettersen, A.; Ryden-Landergren, M.; Barlind, J.; Llinas, A.; Hersloef, M.; Drmota, T.; Sigfridsson, K.; Moses, S.; Whatling, C. Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases J. Med. Chem. 2015, 58, 897-911 10.1021/jm501531v